Paper28367239
Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
Zheng Z and 9 others. J Cancer, 2017. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations. Papers, record 28367239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28367239
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19692684 | Screening for epidermal growth factor receptor mutations in lung cancer. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19692684 | PubMed |
| 2 | 17085664 | Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/17085664 | PubMed |
| 3 | 18779611 | Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18779611 | PubMed |
| 4 | 15197804 | Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. | Cancer | 2004 | https://conductscience.org/library/papers/15197804 | PubMed |
| 5 | 22700443 | Cancer treatment and survivorship statistics, 2012. | CA Cancer J Clin | 2012 | https://conductscience.org/library/papers/22700443 | PubMed |
| 6 | 20195171 | Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. | J Thorac Oncol | 2010 | https://conductscience.org/library/papers/20195171 | PubMed |
| 7 | 12829672 | Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12829672 | PubMed |
| 8 | 25855621 | Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study. | Jpn J Clin Oncol | 2015 | https://conductscience.org/library/papers/25855621 | PubMed |
| 9 | 20573926 | Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20573926 | PubMed |
| 10 | 25034225 | Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation. | Oncology | 2014 | https://conductscience.org/library/papers/25034225 | PubMed |
| 11 | 23341526 | Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23341526 | PubMed |
| 12 | 19680293 | Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. | Oncogene | 2009 | https://conductscience.org/library/papers/19680293 | PubMed |
| 13 | 23871711 | Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients. | Lung Cancer | 2013 | https://conductscience.org/library/papers/23871711 | PubMed |
| 14 | 17008692 | Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/17008692 | PubMed |
| 15 | 23816558 | The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer. | Chin J Cancer | 2014 | https://conductscience.org/library/papers/23816558 | PubMed |
| 16 | 19939491 | Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. | Lung Cancer | 2010 | https://conductscience.org/library/papers/19939491 | PubMed |
| 17 | 25419145 | EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data. | Onco Targets Ther | 2014 | https://conductscience.org/library/papers/25419145 | PubMed |
| 18 | 20677647 | [Estimation and projection of lung cancer incidence and mortality in China]. | Zhongguo Fei Ai Za Zhi | 2010 | https://conductscience.org/library/papers/20677647 | PubMed |
| 19 | 21531810 | Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21531810 | PubMed |
| 20 | 22677429 | Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. | Lung Cancer | 2012 | https://conductscience.org/library/papers/22677429 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41377006 | Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning. | J Thorac Dis | 2025 | https://conductscience.org/library/papers/41377006 | PubMed |
| 40458063 | Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer. | Future Oncol | 2025 | https://conductscience.org/library/papers/40458063 | PubMed |
| 37321664 | Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer. | BMJ Open Respir Res | 2023 | https://conductscience.org/library/papers/37321664 | PubMed |
| 29552210 | Transformation to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma. | Oncol Lett | 2018 | https://conductscience.org/library/papers/29552210 | PubMed |
| 29447182 | The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. | PLoS One | 2018 | https://conductscience.org/library/papers/29447182 | PubMed |
| 29353978 | Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. | Chin J Cancer Res | 2017 | https://conductscience.org/library/papers/29353978 | PubMed |
| 28651600 | Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA). | Radiat Oncol | 2017 | https://conductscience.org/library/papers/28651600 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGF | 1950 | PubTator's text mining | https://conductscience.org/library/genes/1950 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28367239
GET https://conductscience.org/api/papers/v1/28367239/references?page=2